TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In an open-label trial involving 12 people with Parkinson’s disease and mood dysfunction, inflammatory markers were lower after psilocybin treatment, with the study’s inflammatory index remaining below baseline through 30 days. Some mitochondrial-stress marker changes were short-lived, and the findings do not show that psilocybin treats Parkinson’s or that the biomarker shifts caused clinical benefits.
A small, open-label trial in people with Parkinson’s disease and mood dysfunction found that a measure of systemic inflammation was lower than baseline after psilocybin treatment, including 30 days after the higher dose. The results, reported by University of California, San Francisco researchers, are early biomarker findings—not evidence that psilocybin reduces Parkinson’s progression or that inflammation changes explain clinical improvement.
The trial enrolled 12 people with mild-to-moderate Parkinson’s disease, ages 40 to 75. Participants received oral synthetic psilocybin at doses of 10 milligrams and 25 milligrams, about two weeks apart. Blood plasma samples were available from nine participants at baseline, one day after each dose, and 30 days after the 25-milligram dose.
Researchers assessed systemic inflammation using an index combining five measures: interleukin-6, interleukin-8, tumor necrosis factor alpha, interferon gamma and high-sensitivity C-reactive protein. Compared with baseline, the index was lower one day after the 10-milligram dose (standard mean difference, or SMD, -0.72; adjusted P=0.003), one day after the 25-milligram dose (SMD -0.60; adjusted P=0.02) and 30 days after the higher dose (SMD -0.62; adjusted P=0.047), according to the research letter in JAMA Psychiatry.
Other findings were less consistent. Individual components including IL-6 were significantly lower one day after the 10-milligram dose but not at other time points; IL-10 was higher at that same follow-up only. The mitochondrial-stress marker GDF-15 was lower one day after each dose, but not 30 days after the 25-milligram dose. FGF-21 rose after each dose, though the increases were not statistically significant.
What the Biomarker Results Show
The report adds early biological data to research on psychedelic drugs in neurological conditions. The researchers described it as the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease. That makes the findings a starting point for testing whether psilocybin is associated with reproducible changes in inflammation or mitochondrial stress in Parkinson’s disease.
The study does not establish that a lower inflammatory index improves symptoms, protects nerve cells or alters the course of Parkinson’s. Its small size, lack of randomization and absence of a comparison group mean the results cannot show that psilocybin caused the marker changes. The findings are relevant as a research signal, but they do not support using psilocybin as a Parkinson’s treatment outside appropriately supervised research.
psilocybin supplement for mood support
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Parkinson’s Trial Fits
The biomarker analysis was part of a broader trial examining psilocybin therapy in Parkinson’s patients with mood dysfunction. The parent trial reported an association with reductions in depression, anxiety and motor symptoms; that association does not establish that the treatment caused those changes. The new report focuses on blood markers rather than proving a mechanism for any symptom findings.
Most prior research on psilocybin and related psychedelics has focused on mental health conditions, according to Albert Garcia-Romeu, a Johns Hopkins University researcher who was not involved in this study. He said the work adds to investigation of possible biological effects in non-psychiatric conditions. His comments describe the research direction, not proof that psilocybin benefits people with Parkinson’s.
“To our knowledge, this is the first report of changes in these types of markers after psychedelic treatment in people with a neurodegenerative disease.”
— Ellen Bradley, MD, University of California, San Francisco, speaking to MedPage Today
anti-inflammatory supplements for Parkinson’s
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Limits of the Early Findings
The sample was small: 12 people enrolled and plasma results were available for nine. The study was open-label and nonrandomized, so it cannot separate a treatment effect from other influences or establish how the results compare with placebo or usual care. Follow-up for the inflammation index extended to 30 days after the higher dose, leaving longer-term patterns unknown.
It is also unclear whether the changes in blood markers are consistent across a larger Parkinson’s population, whether they relate to meaningful clinical outcomes, or what biological processes might account for them. The reported findings do not establish disease modification, and the mitochondrial-stress results were not sustained across all measures and time points.
mood therapy supplements for Parkinson’s disease
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Controlled Trial Will Test Replication
Bradley and O’Donovan said their group is following up with more detailed analyses of inflammation and mitochondrial stress in a randomized controlled trial involving Parkinson’s patients. That study will be needed to test whether the initial biomarker patterns recur under a stronger design. The source report did not provide a publication date or results timeline for that trial.
Garcia-Romeu also reported that a separate study at his lab is examining psilocybin in people with mild cognitive impairment or early-stage Alzheimer’s disease and depression. He said 18 participants had been treated and 19 of a planned 20 enrolled, with completion and publication expected the following year. That is a separate study and does not confirm the Parkinson’s findings.
natural inflammation reduction products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Parkinson’s trial find?
The study found that a combined systemic inflammation index was lower than baseline at three follow-up points, including 30 days after the 25-milligram dose. It also reported short-lived changes in some mitochondrial-stress markers.
Does this show psilocybin treats Parkinson’s disease?
No. The trial was small, open-label and nonrandomized, and it examined biomarkers. It does not establish that psilocybin treats Parkinson’s, slows its progression or caused the observed marker changes.
How many people took part?
12 people with mild-to-moderate Parkinson’s disease enrolled. Researchers had plasma samples from nine participants for the reported biomarker analysis.
What happens next?
The UCSF researchers said they are examining the findings further in a randomized controlled Parkinson’s trial. Its results will be needed to assess whether the reported changes are reproducible and how they compare with a control group.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
